Natco Pharma Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zc6ztfzkr2l9n5ijrp8ptkzf.pdf

Key Takeaways


The Revlimid Cliff & FY27 Reset

Rajeev Nannapaneni: "I think you need to understand that the nature of this business is that you're going to have one-offs and then you're going to do very well at this time. And then when there's going to be a drop, you're going to have a year or 2 where you're going to see a dip."

Diversification: The Five-Country Base

Rajeev Nannapaneni: "And in a competitive generic environment like ours, it's very difficult to grow organically. You have to grow inorganic. And unless you do these bold acquisitions, you'll not be able to acquire share and size and scale."

Pipeline: The Post-FY27 Promise

Rajeev Nannapaneni: "I would want our base revenue to contribute 70% of our profit and the first to file or special product to contribute 25% to 30%. Earlier, the ratio was the other way around."

Capital Allocation: M&A Over Buybacks


Operational Updates

Rajeev Nannapaneni: "I think the scheme of things, if you just think that you're able to transplant an animal kidney and put that in a human and that human being is able to do well for a few months is an absolutely monumental thing."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenueINR3,400-3,500 croresFY27
FY27 PATINR700-750 crores (includes associate profit)FY27
South African associate revenue$580-600 millionFY27
South African associate PAT$47-48 million (subject to exchange rate and war factors)FY27
Future tax rateAround 25% including surchargeFrom FY27
R&D expenditure7-9% of revenueFY27
Semaglutide India revenueINR75-100 crores annualizedFY27
Brazil subsidiary revenueGrow from ~INR280 crores to INR550-600 croresFY27
Canada subsidiary growth10-15%FY27
U.S. front-end businessBreak evenFY27
Earnings compounding15-25% annuallyStarting FY28, for 2-3 years
Exclusivity launchesBegin contributingFY28 onwards
U.S. ANDA filings8-9 filings, hoping for 1-2 complex first-to-filesFY27
AcquisitionClose 1-2 large deals outside IndiaHoped for in FY27
Adcock Ingram return target15-20% return on capitalOver time (~3-4 years)
Crop Sciences demergerComplete separation for focused managementIn process

Key Metrics

MetricQ4 FY26
Consolidated net revenue₹816.9 cr, vs ₹1,287.3 cr in Q4 FY25
Consolidated net profit (incl. associates)₹269 cr, vs ₹406 cr in Q4 FY25
Onetime tax benefit₹115 cr, from remeasurement of deferred tax assets on move to new tax regime
FY27 revenue guidance₹3,400 cr to ₹3,500 cr
FY27 PAT guidance₹700 cr to ₹750 cr, includes associate profit
Adcock Ingram (associate) revenue₹1,208.2 cr, NATCO share of profit ₹35.7 cr
Adcock Ingram FY27 revenue guidance$580 mn to $600 mn, PAT guidance $47 mn to $48 mn
Net cash (group level)₹2,400 cr
Full-year subsidiary sales₹730 cr
Brazil subsidiary turnover₹257 cr, plus ~₹30 cr direct billing from India
Canada subsidiary turnover₹229 cr
Crop Health Sciences revenue₹140 cr (FY26), vs ₹60 cr prior year
Semaglutide India monthly run rate₹2 cr (own brand), ₹4–5 cr including partners
Semaglutide India annualized expectation₹75 cr to ₹100 cr
R&D and engineering write-down₹20 cr to ₹30 cr in other expenses
U.S. filings completed in FY267 to 8 filings
Future tax rate (new regime)~25%, including surcharge
Brazil FY27 revenue expectation₹550 cr to ₹600 cr
Canada FY27 growth expectation10% to 15%
Agchem raw material cost increase25% to 30%